Dementia Awareness Webinar

June 16, 2026|10:30 AM

As breakthrough Alzheimer's drugs emerge but remain unaffordable for many, dementia's projected rise to 1.4 million UK cases by 2040 demands urgent action on prevention and care in 2026.

Key takeaways

  • New policies like the UK's 10-year health plan target 92% dementia diagnoses within 18 weeks by 2029, addressing the current reality where fewer than half of patients receive timely identification.
  • Lifetime care costs surpassing £4.5 million in severe cases burden families and economies, with global expenses expected to hit $2.8 trillion by 2030 amid an aging population.
  • Advances in blood tests and AI promise faster diagnoses, but tensions arise from NICE rejecting costly new treatments like lecanemab due to insufficient value for NHS resources.

Rising Dementia Challenge

Dementia cases are climbing sharply due to demographic shifts. In the UK, nearly one million people lived with the condition in 2024, a figure set to reach 1.4 million by 2040. Globally, numbers stood at 55 million in 2020 and are forecast to hit 78 million by 2030. This surge stems from longer lifespans, with over one in three Britons born today likely to develop dementia.

Recent scientific strides include approvals for drugs like lecanemab and donanemab in 2024 and 2025, which slow Alzheimer's progression. Yet NICE declined their NHS rollout in June 2025, citing costs five to six times above acceptable thresholds. Blood tests and AI tools, meanwhile, could transform diagnostics, potentially enabling 92% of cases to be identified within 18 weeks by 2029 under new UK targets.

Impacts ripple through societies. In the US, 7.2 million over-65s have Alzheimer's today, projected to reach 13.8 million by 2060. Unpaid caregivers—nearly 12 million—provide 19.2 billion hours annually, valued at $413.5 billion in 2024. In the UK, economic pressures include lost earnings and home modifications, exacerbating inequalities as Black communities face triple the case growth rate.

Stakes involve deadlines like the 2029 diagnosis goal and escalating costs, with global dementia expenses at $1.3 trillion now. Risks of inaction include overwhelmed systems; Wales's 10-year strategy, launched in December 2025, emphasizes prevention, noting half of cases could be delayed via lifestyle changes.

Less visible angles include vascular dementia's role, comprising 15% of cases purely and 31% when mixed with degenerative forms, projected to affect 42.7 million globally by 2050. Tensions emerge between stakeholders: governments push frameworks like England's Modern Service Framework for frailty and dementia, while critics decry the 2025 removal of diagnosis rate targets from NHS planning. Research highlights counterintuitive trends, like a two-thirds drop in age-adjusted US prevalence over 40 years due to better cardiovascular health, offsetting some raw number increases.

Sources

We use cookies to measure site usage. Privacy Policy